New Model of Integrated Care of Older Patients With Atrial Fibrillation in Rural China
MIRACLE-AF
A New Model of Integrated Care of Older Patients With Atrial Fibrillation in Rural China: a Cluster Randomization Trial (the MIRACLE-AF Trial)
1 other identifier
interventional
1,039
1 country
1
Brief Summary
This cluster randomization study aims to compare the village-doctor led telemedicine integrated care versus usual care to improve compliance with the Atrial Fibrillation Better Care (ABC) pathway components and outcomes for older patients with atrial fibrillation in rural China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable atrial-fibrillation
Started Dec 2020
Typical duration for not_applicable atrial-fibrillation
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 18, 2020
CompletedFirst Posted
Study publicly available on registry
November 10, 2020
CompletedStudy Start
First participant enrolled
December 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2024
CompletedJuly 26, 2024
July 1, 2024
3.4 years
October 18, 2020
July 25, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Primary Outcome of Stage 1: The proportion of patients who met all the three criteria for the ABC pathway of integrated AF care
The 'A' criterion referred to stroke prevention or anticoagulation. 'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) \>65%. Patients who were not properly treated with OACs are considered as 'A non-compliant'. The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control. Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant'). On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled. The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities. 'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated. Otherwise, patients were considered as 'C non-compliant'
12 months after baseline
Primary Outcome of Stage 2: The composite of cardiovascular death, all stroke, worsening of heart failure or acute coronary syndrome, and emergency visits due to AF
Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin. Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular death. All strokes included ischemic stroke and hemorrhagic stroke. A worsening of heart failure or acute coronary syndrome was defined as the need to be hospitalized or have an emergency visit in conjunction with these conditions
36 months after baseline
Secondary Outcomes (11)
Secondary Outcome of Stage 1: The proportions of patients who meet the criterion for the A component in the ABC pathway
12 months after baseline
Secondary Outcome of Stage 1: The proportions of patients who meet the criterion for the B component in the ABC pathway
12 months after baseline
Secondary Outcome of Stage 1: The proportions of patients who meet the criterion for the C component in the ABC pathway
12 months after baseline
Secondary Outcome of Stage 2: All-cause mortality
36 months after baseline
Secondary Outcome of Stage 2: Cardiovascular death
36 months after baseline
- +6 more secondary outcomes
Study Arms (2)
Village doctor-led telemedicine integrated care
EXPERIMENTALTo empower village doctors, a new technology-based model of AF care was established in the intervention group. A digital health support platform was developed by our research team, and a network of teams consisting of village doctors and AF specialists in our research team was established in the intervention group. With the aid of this telemedicine platform, village doctors can receive more support from AF specialists in providing integrated AF care to the rural elderly with AF.
Enhanced usual care
ACTIVE COMPARATORUsual care plus intensified education to patients, their family members, and their village doctors.
Interventions
1\. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
1\. Usual care; 2. Intensified education to patients, their family members, and their village doctors.
Eligibility Criteria
You may qualify if:
- \. The village clinics need to be willing and able to provide integrated care to their patients with atrial fibrillation; 2. The village doctors from one village clinic serves all AF patients from 3-5 nearby villages; 3. The village doctors are trained to have a fundamental understanding of telemedicine; 4. Patients are eligible for participation if 1) they are aged 65 years or above; 2) they are diagnosed atrial fibrillation by an ECG, AF specialist, or hospital discharge letter; 3) they agree to receive the medical care provided by village clinics; 4) they provide written informed consent.
You may not qualify if:
- Moderate to severe rheumatic mitral stenosis or heart valve replacement history.
- Presence of ICD or CRT device.
- Pulmonary vein isolation or left atrial appendage occlusion history or plan to perform any of the above operations.
- The life expectancy is less than 1 year.
- Participation in other clinical trials.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 201129, China
Related Publications (2)
Chu M, Zhang S, Gong J, Yang S, Yang G, Sun X, Wu D, Xia Y, Jiao J, Peng X, Peng Z, Hong L, Wang Z, Li M, Lip GYH, Chen M; MIRACLE-AF Investigators. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med. 2025 Apr;31(4):1276-1285. doi: 10.1038/s41591-025-03511-2. Epub 2025 Feb 21.
PMID: 39984634DERIVEDLi M, Chu M, Shen Y, Zhang S, Yin X, Yang S, Lip GYH, Chen M; MIRACLE-AF Trial Investigators. A Novel Model of Integrated Care of Older Patients With Atrial Fibrillation in Rural China. JACC Asia. 2024 Jul 30;4(10):764-773. doi: 10.1016/j.jacasi.2024.07.006. eCollection 2024 Oct.
PMID: 39553909DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Minglong Chen, MD
The First Affiliated Hospital with Nanjing Medical University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Outcome assessment committee members will be blinded to the group assignment.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy Director of the Department of Cardiology
Study Record Dates
First Submitted
October 18, 2020
First Posted
November 10, 2020
Study Start
December 1, 2020
Primary Completion
May 9, 2024
Study Completion
May 30, 2024
Last Updated
July 26, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share